NASDAQ:ISRG 22 June 2025 - 15 December 2025

Intuitive Surgical, Inc. is back in focus on December 15, 2025, as the robotic-surgery leader sees fresh attention from institutional-filing headlines, ETF flow commentary, and options-market activity—all landing on the same day the stock trades higher. While there wasn’t a single blockbuster earnings release or acquisition announced today, the day’s coverage paints a clear picture of why ISRG remains one of the most closely watched large-cap medtech names: it’s a dominant platform business with recurring revenue characteristics, strong procedure momentum, and a valuation that keeps Wall Street debating how much growth is already priced in.

Updated: Friday, December 12, 2025Company: Intuitive Surgical, Inc. Intuitive Surgical stock finished the week on the back foot—even as the robotic-surgery leader delivered a meaningful regulatory win. Shares of ISRG closed at $542.32 on Friday, Dec. 12, capping a five-session slide from $566.89 on Monday, Dec. 8. Nasdaq

Intuitive Surgical, Inc. finished the regular session on Friday, December 12, 2025, lower—but after-hours trading stayed quiet, suggesting no major late-breaking catalyst hit the tape after the closing bell. ISRG closed at $542.32, down $5.04, after trading between $537.70 and $548.93 on the day, with about 2.08 million shares traded. Yahoo Finance+1 After the close, the stock was essentially flat, trading around $542.00 in late after-hours activity. Yahoo Finance

Intuitive Surgical, Inc. ended Friday’s session lower, then traded almost flat after the bell as investors digested a busy mix of analyst calls, options-market signals, and fresh SEC-related headlines. Below is a detailed wrap of what moved ISRG on Dec. 12, 2025 after hours, plus the key news, forecasts, and analysis published on 12/12/2025 that traders will likely carry into the next regular session.

Intuitive Surgical Inc., the robotics and minimally invasive surgery leader behind the da Vinci and Ion platforms, continues to trade near the top of its 52‑week range as of December 7, 2025. Specialist services that track Intuitive Surgical’s price history also show a strong rebound over the last three months, with shares approaching their late‑January 2025 high around $616. StockInvest+1

Intuitive Surgical Stock on December 2, 2025: Da Vinci 5 Momentum, Insider Sale and 2026 Wall Street Forecasts All figures in USD. Data current as of the close on December 1, 2025 and latest analyst/market reports available on December 2, 2025.

As U.S. markets get ready to open on Monday, December 1, 2025, Intuitive Surgical, Inc. heads into the new month sitting near the top of its 52‑week range after a powerful earnings rally, heavy institutional activity, and fresh AI‑driven research coverage. At the last full trading session on Friday, November 28, 2025, Intuitive Surgical stock closed around $573.5 per share, down only a fraction on the day but up strongly over the past month and quarter. That price implies a market capitalization of roughly $203–205 billion and leaves the stock less than 10% below recent 52‑week highs in the low $600s. TS2 Tech+4StockAnalysis+4MarketBeat+4

Intuitive’s stock has been volatile in 2025. It gained ground last week on optimism and now sits around $446 investing.com marketbeat.com. Over the past year, the price swung between about $425 and $616 investing.com. At ~$446, ISRG trades at a high single-digit P/E compared to the medtech sector, but analysts argue much of Intuitive’s growth is already priced in. Institutional sentiment is upbeat: 22 of 32 surveyed analysts rate ISRG a Buy, with an average 12-month target of roughly $576 investing.com. For example, RBC Capital recently reiterated an “Outperform” rating with a $615 target, and Truist maintains a Buy marketbeat.com. MarketBeat’s consensus is ~$582 marketbeat.com, and simplywall.st’s fair-value model arrives at ~$582 as well simplywall.st. Fundamentals are strong: Intuitive’s revenue has grown steadily, and its long-term EPS growth is among the best in medtech. The company carries a pristine balance sheet and has approved $3–4B in buybacks over time. Key risks include international tariffs globenewswire.com and potential hospital CapEx pullbacks. But with interest in robotic surgery rising globally, most Wall Street models still assume double-digit revenue growth through 2026.